{"organizations": [], "uuid": "d3c7731d0455d2cda3379e428a21ecde4782674e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-gb-sciences-pursues-fda-registered/brief-gb-sciences-pursues-fda-registered-first-in-human-trial-of-cannabis-based-therapy-for-parkinsons-disease-idUSFWN1RN06W", "country": "US", "domain_rank": 408, "title": "BRIEF-GB Sciences Pursues FDA-Registered, First-In-Human Trial Of Cannabis Based Therapy For Parkinson's Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-10T12:35:00.000+03:00", "replies_count": 0, "uuid": "d3c7731d0455d2cda3379e428a21ecde4782674e"}, "author": "", "url": "https://www.reuters.com/article/brief-gb-sciences-pursues-fda-registered/brief-gb-sciences-pursues-fda-registered-first-in-human-trial-of-cannabis-based-therapy-for-parkinsons-disease-idUSFWN1RN06W", "ord_in_thread": 0, "title": "BRIEF-GB Sciences Pursues FDA-Registered, First-In-Human Trial Of Cannabis Based Therapy For Parkinson's Disease", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "parkinson’s", "sentiment": "none"}, {"name": "gb sciences inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "human trial of cannabis based therapy for parkinson's disease reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 10 (Reuters) - GB Sciences Inc:\n* BASED THERAPY FOR PARKINSON’S DISEASE * EXPECTS TO COMMENCE ITS FIRST-IN-HUMAN TRIAL IN EARLY 2019\n* COMPANY WILL BEGIN ITS TOXICOLOGY STUDIES IN SUMMER OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-10T12:35:00.000+03:00", "crawled": "2018-04-10T12:49:33.006+03:00", "highlightTitle": ""}